ClinicalTrials.gg
CompletedNCT04188730Updated Jun 15, 2022Results posted

A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

A Phase 1 interventional study of Lofexidine (granules for reconstitution) and LUCEMYRA (lofexidine) tablets in Normal Healthy Volunteers, sponsored by USWM, LLC (dba US WorldMeds). Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this open-label, single-dose, randomized, three-treatment, three-period, four-sequence, crossover study is to evaluate the relative bioavailability of a test formulation of lofexidine granules for reconstitution (oral) and LUCEMYRA tablets under fasted conditions and to evaluate the effect of food on the relative bioavailability of lofexidine granules for reconstitution (oral) when administered under fed compared to fasted conditions.

02

Conditions studied

  • Normal Healthy Volunteers
03

In context

Lead sponsor

USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, 18-50 years of age, inclusive, with a (BMI) of 20.0-35.0 kg/m², inclusive.
  2. Female subjects must meet at least one of the following criterion:

    • Agree to abstain from sexual intercourse from screening and throughout the duration of the study.
    • Have used and agree to continue to use a reliable method of (e.g., condom with spermicide, IUD, hormonal contraceptives) for at least 30 days before initial dosing and throughout the duration of the study.
    • Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation or Essure® device placement at least 3 months prior to initial dosing).
    • At least 1 year and have a documented FSH level ≥ 40 mIU/mL at screening.
  3. Good health as determined by lack of abnormalities in health assessments performed at screening.
  4. Signed and dated form, which meets all criteria of current FDA regulations.

Exclusion criteria

Exclusion Criteria

  1. Females who are pregnant, lactating, or likely to become pregnant during the study.
  2. History of allergy or sensitivity to lofexidine or any component of the study drug or history of any drug or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  3. Significant history or current evidence of chronic infectious disease, system disorders, or organ dysfunction, especially cardiovascular disorders (e.g., severe coronary insufficiency, recent myocardial infarction [within 1 year before initial dosing], cerebrovascular disease), respiratory disorders, congenital long syndrome, diabetes, hepatic or renal disorders (e.g., chronic renal failure).
  4. Pulse \< 50 bpm or symptomatic bradycardia, as determined by the Investigator.
  5. history of hypotension, as determined by the Investigator, or has a sitting/supine systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg, or hypertension, as determined by the Investigator, or has sitting/supine systolic blood pressure > 190 mmHg and/or diastolic > 95 mmHg; determined at screening.
  6. Experiences reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing from a resting (sitting or supine) position; determined at screening.
  7. 12-lead , conducted in triplicate, considered by the Investigator to be clinically significant (e.g., second or third degree heart block, uncontrolled arrhythmia) or has a QTcF (Fridericia's correction) interval > 440 msec in 2 of the 3 ECGs performed; determined at screening.
  8. Clinically significant history or presence of any gastrointestinal disease or history of malabsorption within the last year, as determined by the Investigator.
  9. History of any psychiatric disorders occurring within the last two years that required the subject to be hospitalized or treated with medication.
  10. Subject has history of suicidality based on responses provided on the Columbia-Suicide Severity Rating Scale (C-SSRS), or is at risk for self-harm or harm to others based on clinical interview, at the discretion of the Investigator.
  11. Ingestion of grapefruit-containing food or beverages (e.g., Fresca®) within 7 days before dosing.
  12. Drug or alcohol addiction requiring treatment in the 12 months before initial dosing.
  13. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.
  14. Positive test results for , surface antigen, or antibody.
  15. Positive test results for drugs of abuse (benzodiazepines, cocaine, cannabinoids/THC, opiates and at screening only: amphetamines, barbiturates, methadone and phencyclidine).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Lofexidine (granules for reconstitution), fasted

    Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.

    Drug: Lofexidine (granules for reconstitution)

  • Active comparator
    LUCEMYRA (lofexidine) tablets, fasted

    Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours

    Drug: LUCEMYRA (lofexidine) tablets

  • Experimental
    Lofexidine (granules for reconstitution), fed

    Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.

    Drug: Lofexidine (granules for reconstitution)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Maximum Plasma Concentration (Cmax)

    The peak exposure plasma concentrations (Cmax) of lofexidine were observed and measured.

    Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.

  2. Time to Maximum Plasma Concentration (Tmax)

    Time to peak plasma concentration (h) collection time at which Cmax is first observed.

    Time frame: Day 1 through Day 3 for Periods I, II, III.

  3. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t)

    Areas under the plasma concentration-time curve from time zero to the time of last measurable concentration (AUC0-t)

    Time frame: Day 1 through Day 3 for Periods I, II, III.

  4. Area Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞)

    Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.

  5. First-order Terminal Rate Constant (λz)

    Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.

  6. First-order Terminal Half-life (T½)

    Time frame: Mean from Day 1 through Day 3 for Periods I, II, III.

Secondary outcomes

  1. Occurrence of Adverse Events (AEs)

    Number of Subjects dosed for each Treatment groups: Treatment A = 15 subjects dosed; Treatment B = 16 subjects dosed; Treatment C = 15 subjects dosed

    Time frame: Total from occurrences assessed daily after each dosing for Periods 1-3, as well as end of study (22 days)

07

Results

Posted Jun 15, 2022

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: Treatment B, Treatment A, Treatment CSequence 2: Treatment B, Treatment C, Treatment ASequence 3: Treatment A, Treatment C, Treatment BSequence 4: Treatment C, Treatment A, Treatment B
Started4444
Period 14444
Period 23444
Period 33444
Completed3444
Not completed1000

Outcome measures

PrimaryMean Maximum Plasma Concentration (Cmax)

The peak exposure plasma concentrations (Cmax) of lofexidine were observed and measured.

Time frame:
Mean from Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · ng/mL
Mean Maximum Plasma Concentration (Cmax)
ng/mLTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Mean Maximum Plasma Concentration (Cmax)0.6984 ± 0.16610.7275 ± 0.16570.6977 ± 0.1656
PrimaryTime to Maximum Plasma Concentration (Tmax)

Time to peak plasma concentration (h) collection time at which Cmax is first observed.

Time frame:
Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax)
hoursTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Time to Maximum Plasma Concentration (Tmax)4.2678 ± 1.38944.3367 ± 1.23644.5344 ± 1.6435
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t)

Areas under the plasma concentration-time curve from time zero to the time of last measurable concentration (AUC0-t)

Time frame:
Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t)
h*ng/mLTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-t)12.1333 ± 4.96512.2450 ± 4.14212.4540 ± 4.517
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞)
Time frame:
Mean from Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · h·ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞)
h·ng/mLTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Area Under the Plasma Concentration-time Curve From Time Zero to Time Infinity (AUC0-∞)14.9643 ± 6.06314.7229 ± 4.41114.9004 ± 5.021
PrimaryFirst-order Terminal Rate Constant (λz)
Time frame:
Mean from Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · h^-1
First-order Terminal Rate Constant (λz)
h^-1Treatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
First-order Terminal Rate Constant (λz)0.0549 ± 0.01500.0524 ± 0.00710.0524 ± 0.0075
PrimaryFirst-order Terminal Half-life (T½)
Time frame:
Mean from Day 1 through Day 3 for Periods I, II, III.
Reported as:
Mean · hours
First-order Terminal Half-life (T½)
hoursTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
First-order Terminal Half-life (T½)13.5577 ± 3.90113.4681 ± 1.88113.5008 ± 2.068
SecondaryOccurrence of Adverse Events (AEs)

Number of Subjects dosed for each Treatment groups: Treatment A = 15 subjects dosed; Treatment B = 16 subjects dosed; Treatment C = 15 subjects dosed

Time frame:
Total from occurrences assessed daily after each dosing for Periods 1-3, as well as end of study (22 days)
Reported as:
Number · adverse events
Occurrence of Adverse Events (AEs)
adverse eventsTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Occurrence of Adverse Events (AEs)31314

Adverse events

Collected over Daily after each dosing for Periods 1-3, as well as End of Study Day 3 Period 3 (22 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Lofexidine Granules - Fasted Conditions0/15 (0%)0/15 (0%)3/15 (20%)
Treatment B: LUCEMYRA Tablets - Fasted Conditions0/16 (0%)0/16 (0%)8/16 (50%)
Treatment C: Lofexidine Granules - Fed Conditions0/15 (0%)0/15 (0%)7/15 (46.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment A: Lofexidine Granules - Fasted ConditionsTreatment B: LUCEMYRA Tablets - Fasted ConditionsTreatment C: Lofexidine Granules - Fed Conditions
Blood pressure decreasedInvestigations2/154/164/15
SomnolenceNervous system disorders1/154/163/15
Decreased appetiteMetabolism and nutrition disorders0/150/162/15
Alanine aminotransferase increasedInvestigations0/150/161/15
NauseaGastrointestinal disorders0/151/161/15
Abdominal painGastrointestinal disorders0/150/161/15
Abdominal pain upperGastrointestinal disorders0/150/161/15
PainGeneral disorders0/150/161/15
DizzinessNervous system disorders0/151/160/15
HeadacheNervous system disorders0/151/160/15

Baseline characteristics

This is a crossover study with an enrollment of sixteen (16) healthy adult subjects. Each subject was eligible to participate in all 3 treatment group (Treatment A, Treatment B, Treatment C).

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years16
>=65 years0
Age, Continuous
Age, Continuous(years)All Study Participants
Mean35.1 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female3
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native3
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American9
White4
More than one race0
Unknown or Not Reported0
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)All Study Participants
Mean28.5 ± 3.2
Height
Height(cm)All Study Participants
Mean175.1 ± 8.4
Weight
Weight(kg)All Study Participants
Mean88.0 ± 14.6
Tobacco Users
Tobacco Users(Count of participants)All Study Participants
Yes0
No16
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Las Vegas, Nevada 89121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Mar 2021, 1 month.

Results were first posted in Jun 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Dec 6, 2019
StartActual
Feb 16, 2021
Primary completionActual
Mar 26, 2021
CompletionActual
Mar 26, 2021
Results first posted
Jun 15, 2022
Last update
Jun 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04188730
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Dec 6, 2019
Start date
Feb 16, 2021
Primary completion
Mar 26, 2021
Completion
Mar 26, 2021
Results posted
Jun 15, 2022
Last update
Jun 15, 2022

Study contacts

Kim New
study director · USWM, LLC (dba US WorldMeds)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion